(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94583 A2

(51) International Patent Classification[7]: C12N 15/12, C07K 14/47

(21) International Application Number: PCT/US01/18393

(22) International Filing Date: 6 June 2001 (06.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/210,045 7 June 2000 (07.06.2000) US

(71) Applicant: **LEXICON GENETICS INCORPORATED** [US/US]; 4000 Research Forest Drive, The Woodlands, TX 77381 (US).

(72) Inventors: **WALKE, D., Wade**; 7507 Danehill Drive, Spring, TX 77389 (US). **SCOVILLE, John**; 8222 Kingsbrook Dr. #543, Houston, TX 77024 (US).

(74) Agents: **ISHIMOTO, Lance, K.** et al.; Lexicon Genetics Incorporated, 4000 Research Forest Drive, The Woodlands, TX 77381 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/94583 A2

(54) Title: NOVEL HUMAN TRANSPORTER PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME

(57) Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomicapplications.

# NOVEL HUMAN TRANSPORTER PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME

The present application claims the benefit of U.S. Provisional Application Number 60/210,045 which was filed on June 7, 2000 and is herein incorporated by reference in its entirety.

## 1. INTRODUCTION

The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins that share sequence similarity with mammalian transporter proteins. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that either lack or over express the disclosed polynucleotide sequences, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed polynucleotide sequences that can be used for diagnosis, drug screening, clinical trial monitoring, the treatment of diseases and disorders, and cosmetic or nutriceutical applications.

## 2. BACKGROUND OF THE INVENTION

Transporter proteins are integral membrane proteins that mediate or facilitate the passage of materials across the lipid bilayer. Given that the transport of materials across the membrane can play an important physiological role, transporter proteins are good drug targets. Additionally, one of the mechanisms of drug resistance involves diseased cells using cellular transporter systems to export

chemotherapeutic agents from the cell. Such mechanisms are particularly relevant to cells manifesting resistance to a multiplicity of drugs.

## 3. SUMMARY OF THE INVENTION

The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with mammalian ion transporters, sulfate transporters, and particularly the sulfate transporter that has been associated with diastrophic dysplasia.

The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 679, 621, 663, 605, 656, and 598 amino acids in length (see respectively SEQ ID NOS: 2, 4, 6, 8, 10, and 12. The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof, that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (*e.g.*, antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (*e.g.*, expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or "knock-outs" (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cells ("ES cells") lines that contain gene trap mutations in a murine homolog of at least

one of the described NHPs. When the unique NHP sequences described in SEQ ID NOS:1-13 are "knocked-out" they provide a method of identifying phenotypic expression of the particular gene as well as a method of assigning function to previously unknown genes. Additionally, the unique NHP sequences described in SEQ ID NOS:1-13 are useful for the identification of coding sequence and the mapping a unique gene to a particular chromosome.

Further, the present invention also relates to processes for identifying compounds that modulate, *i.e.*, act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

## 4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing provides the sequences of NHP ORFs encoding the described NHP amino acid sequences. SEQ ID NO:13 shows a NHP ORF and flanking regions.

## 5. DETAILED DESCRIPTION OF THE INVENTION

The NHPs described for the first time herein are novel proteins that may be expressed in, *inter alia,* human cell lines, pituitary, lymph node, kidney, testis, thyroid, heart, placenta, adipose, placenta, trachea, umbilical vein endothelium, fetal brain, and fetal kidney cells.

The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described polynucleotide sequences, including the

specifically described NHPs, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal (or hydrophobic transmembrane) sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of an NHP, or one of its domains (*e.g.*, a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in the Sequence Listing.

As discussed above, the present invention includes: (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, *e.g.*, hybridization to filter-bound DNA in 0.5 M $NaHPO_4$, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and

encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, *e.g.*, washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*), yet still encodes a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Patent Nos. 5,837,458 and 5,723,323 both of which are herein incorporated by reference in their entirety). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP gene nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that

incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput "chip" format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. An oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one or more of the sequences of SEQ ID NOS: 1-13 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (*i.e.*, gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the sequences of SEQ ID NOS: 1-13, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing biopolymers on, solid support matrices, and conducting binding studies thereon are disclosed in, *inter alia*, U.S. Patent Nos. 5,700,637, 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405 the disclosures of which are herein incorporated by reference in their entirety.

Addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-13 can be used to identify and characterize the temporal and tissue specific expression of a gene. These addressable arrays incorporate oligonucleotide sequences of sufficient length to confer the required specificity,. yet be within the limitations of the production technology. The length of these probes is within a range of between about 8 to about 2000 nucleotides. Preferably the probes consist of 60 nucleotides and more preferably 25 nucleotides from the sequences first disclosed in SEQ ID NOS:1-13.

For example, a series of the described oligonucleotide sequences, or the complements thereof, can be used in chip format to represent all or a portion of the described sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other and/or the sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 8 nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences can begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

Microarray-based analysis allows the discovery of broad patterns of genetic activity, providing new understanding of gene functions and generating novel and unexpected insight into transcriptional processes and biological mechanisms. The use of addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-13 provides detailed information about transcriptional changes involved in a specific pathway,

potentially leading to the identification of novel components or gene functions that manifest themselves as novel phenotypes.

Probes consisting of sequences first disclosed in SEQ ID NOS:1-13 can also be used in the identification, selection and validation of novel molecular targets for drug discovery. The use of these unique sequences permits the direct confirmation of drug targets and recognition of drug dependent changes in gene expression that are modulated through pathways distinct from the drugs intended target. These unique sequences therefore also have utility in defining and monitoring both drug action and toxicity.

As an example of utility, the sequences first disclosed in SEQ ID NOS:1-13 can be utilized in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. These investigations can also be carried out using the sequences first disclosed in SEQ ID NOS:1-13 *in silico* and by comparing previously collected genetic databases and the disclosed sequences using computer software known to those in the art.

Thus the sequences first disclosed in SEQ ID NOS:1-13 can be used to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay.

Although the presently described sequences have been specifically described using nucleotide sequence, it should be appreciated that each of the sequences can uniquely be described using any of a wide variety of additional structural attributes, or combinations thereof. For example, a given sequence can be described by the net composition of the nucleotides present within a given region of the sequence in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in the SEQ ID

NOS: 1-13. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences can be used to structurally describe a given sequence. Such restriction maps, which are typically generated by widely available computer programs (*e.g.*, the University of Wisconsin GCG sequence analysis package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, MI, etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the sequence that can be described by the relative position of the sequence relatve to one or more additional sequence(s) or one or more restriction sites present in the disclosed sequence.

For oligonucleotide probes, highly stringent conditions may refer, *e.g.*, to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-

galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. *15*:6625-6641). The oligonucleotide is a 2'-0-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. *15*:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. *215*:327-330).

Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. *16*:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. *85*:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within

the exons, introns, splice sites (*e.g.*, splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or "wobble" oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (*i.e.*, one known, or suspected, to express a NHP gene). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified

fragment can be isolated. For a review of cloning strategies that can be used, see *e.g.*, Sambrook *et al.*, 1989, *supra*.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (*e.g.*, a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure, connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor, NY.)

Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (*e.g.*, as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (*i.e.*, antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculo virus as described in U.S. Patent No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences

in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (*i.e.*, gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α-mating factors.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (*e.g.*, expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enhancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered

cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding to NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, *i.e.*, fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater detail in the subsections below.

## 5.1 THE NHP SEQUENCES

The cDNA sequences and the corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides were obtained from clustered human ESTs, human thyroid RACE products, and cDNAs from kidney and thyroid libraries (Edge Biosystems, Gaithersburg, MD). The described NHPs are similar to eucaryotic sulfate transporters and human pendrin. A particularly similar sulfate transporter has been associated with diastrophic dysplasia which has been associated with dwarfism, inherited chondrodysplasia, and osseous dysplasia I. Accordingly, the described NHPs can be useful in detecting and treating such conditions.

A polymorphism was detected consisting of an A-T transversion at the sequence region represented by, for example, nucleotide number 1454 of SEQ ID NO:1 which can result in a corresponding E or V being present at amino acid position 485 of, for example, SEQ ID NO:2.

Transporters and transporter related multidrug resistance (MDR) sequences, as well as uses and applications that are germane to the described NHPs, are described in U.S. Patents Nos. 5,198,344 and 5,866,699 which are herein incorporated by reference in their entirety.

An additional application of the described novel human polynucleotide sequences is their use in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the described novel sequences using, for example, polynucleotide shuffling or related methodologies. Such approaches are described in U.S. Patents Nos. 5,830,721 and

5,837,458 which are herein incorporated by reference in their entirety.

NHP gene products can also be expressed in transgenic animals. Animals of any species, including, but not limited to, worms, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, birds, goats, and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate NHP transgenic animals.

Any technique known in the art may be used to introduce a NHP transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, 1985, Proc. Natl. Acad. Sci., USA *82*:6148-6152); gene targeting in embryonic stem cells (Thompson *et al.*, 1989, Cell *56*:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. *3*:1803-1814); and sperm-mediated gene transfer (Lavitrano *et al.*, 1989, Cell *57*:717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. *115*:171-229, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the NHP transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or somatic cell transgenic animals. The transgene may be integrated as a single transgene or in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.*, 1992, Proc. Natl. Acad. Sci. USA *89*:6232-6236. The regulatory

sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that a NHP transgene be integrated into the chromosomal site of the endogenous NHP gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous NHP gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous NHP gene (*i.e.*, "knockout" animals).

The transgene can also be selectively introduced into a particular cell type, thus inactivating the endogenous NHP gene in only that cell type, by following, for example, the teaching of Gu *et al.*, 1994, Science, *265*:103-106. The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant NHP gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR. Samples of NHP gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the NHP transgene product.

## 5.2 NHPS AND NHP POLYPEPTIDES

NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include but are not limited to the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be used as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc,) in order to treat disease, or to therapeutically augment the efficacy of, for example, chemotherapeutic agents used in the treatment of breast or prostate cancer.

The Sequence Listing discloses the amino acid sequences encoded by the described NHP genes. The NHPs typically display have initiator methionines in DNA sequence contexts consistent with a translation initiation site.

The NHP amino acid sequences of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein,

the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell *et al.* eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria, including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (*e.g.*, proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention.

Where, as in the present instance, the NHP peptide or polypeptide is thought to be membrane protein, the hydrophobic regions of the protein can be excised and the resulting soluble peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, *in situ*. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the NHP, but to assess biological activity, *e.g.*, in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (*e.g.*, *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (*e.g.*, *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (*e.g.*, COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian

viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther *et al.*, 1983, EMBO J. *2*:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. *13*:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. *264*:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene)

of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (*e.g.*, see Smith *et al.*, 1983, J. Virol. *46*:584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (*e.g.*, See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA *81*:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in

phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bitter *et al.*, 1987, Methods in Enzymol. *153*:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (*e.g.*, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and

a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NHP product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, *et al.*, 1977, Cell *11*:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA *48*:2026), and adenine phosphoribosyltransferase (Lowy, *et al.*, 1980, Cell *22*:817) genes can be employed in $tk^-$, $hgprt^-$ or $aprt^-$ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, *et al.*, 1980, Natl. Acad. Sci. USA *77*:3567; O'Hare, *et al.*, 1981, Proc. Natl. Acad. Sci. USA *78*:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA *78*:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, J. Mol. Biol. *150*:1); and hygro, which confers resistance to hygromycin (Santerre, *et al.*, 1984, Gene *30*:147).

Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by

Janknecht *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, *et al.*, 1991, Proc. Natl. Acad. Sci. USA *88*:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto $Ni^{2+}$·nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

Also encompassed by the present invention are fusion proteins that direct the NHP to a target organ and/or facilitate transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching the appropriate signal sequence to the NHP would also transport the NHP to the desired location within the cell. Alternatively targeting of NHP or its nucleic acid sequence might be achieved using liposome or lipid complex based delivery systems. Such technologies are described in "Liposomes:A Practical Approach", New,RRC ed., Oxford University Press, New York and in U.S. Patents Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures which are herein incorporated by reference in their entirety. Additionally embodied are novel protein constructs engineered in such a way that they facilitate transport of the NHP to the target site or desired organ. This goal may be achieved by coupling of the NHP to a cytokine or other ligand that provides targeting specificity, and/or to a protein transducing domain (see generally U.S. applications Ser. No. 60/111,701 and 60/056,713, both of which are herein incorporated by reference, for examples of

such transducing sequences) to facilitate passage across cellular membranes if needed and can optionally be engineered to include nuclear localization sequences when desired.

## 5.3 ANTIBODIES TO NHP PRODUCTS

Antibodies that specifically recognize one or more epitopes of a NHP, or epitopes of conserved variants of a NHP, or peptide fragments of a NHP are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, $F(ab')_2$ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

The antibodies of the invention may be used, for example, in the detection of NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of NHP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of a NHP gene product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals may be immunized by injection with a NHP, an NHP peptide (*e.g.*, one corresponding to a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains

have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diptheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature *256*:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor *et al.*, 1983, Immunology Today *4*:72; Cole *et al.*, 1983, Proc. Natl. Acad. Sci. USA *80*:2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of

mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, Proc. Natl. Acad. Sci., *81*:6851-6855; Neuberger *et al.*, 1984, Nature, *312*:604-608; Takeda *et al.*, 1985, Nature, *314*:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety. Also encompassed by the present invention is the use of fully humanized monoclonal antibodies as described in US Patent No. 6,150,584 and respective disclosures which are herein incorporated by reference in their entirety.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science *242*:423-426; Huston *et al.*, 1988, Proc. Natl. Acad. Sci. USA *85*:5879-5883; and Ward *et al.*, 1989, Nature *341*:544-546) can be adapted to produce single chain antibodies against NHP gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the $F(ab')_2$

fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, *246*:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, *e.g.*, Greenspan & Bona, 1993, FASEB J *7(5)*:437-444; and Nissinoff, 1991, J. Immunol. *147(8)*:2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that "mimic" the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP mediated pathway.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are herein incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising at a nucleotide sequence encoding an amino acid sequence drawn from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, and 12.

2. An isolated nucleic acid molecule comprising a nucleotide sequence that:

(a) encodes the amino acid sequence shown in SEQ ID NO: 10; and

(b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:9 or the complement thereof.

3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:10.

4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:4.

5. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:2.

SEQUENCE LISTING

<110> LEXICON GENETICS INCORPORATED

<120> Novel Human Transporter Proteins and Polynucleotides Encoding the Same

<130> LEX-0186-PCT

<150> US 60/210,045
<151> 2000-06-07

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2040
<212> DNA
<213> homo sapiens

<400> 1
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag 60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat 120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa 180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta 240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc 300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct 360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt 420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg 480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc 540
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga 600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt 660
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc 720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct 780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac 840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc 900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat 960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac 1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata 1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag 1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg 1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg 1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaata 1320
tgggtcagta catatgtatt tacaatatgc tttgctgcca atgtgggact gctgtttggt 1380
gttgtttgta ccatagctat agtgatagga cgcttcccaa gagcaatgac tgtaagtata 1440
aaaaatatga aagwaatgga atttaaagtg aagacagaaa tggacagtga aaccctgcag 1500
caggtgaaaa ttatctcaat aaacaacccg cttgttttcc tgaatgcaaa aaaatttat 1560
actgatttaa tgaacatgat ccaaaaggaa aatgcctgta atcagccact tgatgatatc 1620
agcaagtgtg aacaaaacac attgcttaat tccctatcca atggcaactg caatgaagaa 1680
gcttcacagt cctgccctaa tgagaagtgt tatttaatcc tggattgcag tggatttacc 1740
ttttttgact attctggagt ctccatgctt gttgaggttt acatggactg taaaggcagg 1800
agtgtggatg tattgttagc ccattgtaca gcttccttga taaaagcaat gacgtattat 1860
ggaaacctag actcagagaa accaattttt tttgaatcgg tatctgctgc aataagtcat 1920
atccattcaa ataagatgga gtctcgctct gtctcccacg ctggagtgtc gcgatctcgg 1980

ctcactgcaa gctccgcctc ccgggttcac gcctttctcc tgcctcagcc tctcgagtag 2040

<210> 2
<211> 679
<212> PRT
<213> homo sapiens

<400> 2

```
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
 1               5                  10                  15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
            20                  25                  30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
        35                  40                  45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
    50                  55                  60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65                  70                  75                  80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
                85                  90                  95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
            100                 105                 110
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
```

```
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
            420                 425                 430
Val Asp Lys Ile Asp Trp Gly Ile Trp Val Ser Thr Tyr Val Phe Thr
        435                 440                 445
Ile Cys Phe Ala Ala Asn Val Gly Leu Leu Phe Gly Val Val Cys Thr
    450                 455                 460
Ile Ala Ile Val Ile Gly Arg Phe Pro Arg Ala Met Thr Val Ser Ile
465                 470                 475                 480
Lys Asn Met Lys Glu Met Glu Phe Lys Val Lys Thr Glu Met Asp Ser
                485                 490                 495
Glu Thr Leu Gln Gln Val Lys Ile Ile Ser Ile Asn Asn Pro Leu Val
            500                 505                 510
Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp Leu Met Asn Met Ile Gln
        515                 520                 525
Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp Asp Ile Ser Lys Cys Glu
    530                 535                 540
Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn Gly Asn Cys Asn Glu Glu
545                 550                 555                 560
Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys Tyr Leu Ile Leu Asp Cys
                565                 570                 575
Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly Val Ser Met Leu Val Glu
            580                 585                 590
Val Tyr Met Asp Cys Lys Gly Arg Ser Val Asp Val Leu Leu Ala His
        595                 600                 605
Cys Thr Ala Ser Leu Ile Lys Ala Met Thr Tyr Tyr Gly Asn Leu Asp
    610                 615                 620
Ser Glu Lys Pro Ile Phe Phe Glu Ser Val Ser Ala Ala Ile Ser His
625                 630                 635                 640
Ile His Ser Asn Lys Met Glu Ser Arg Ser Val Ser His Ala Gly Val
                645                 650                 655
Ser Arg Ser Arg Leu Thr Ala Ser Ser Ala Ser Arg Val His Ala Phe
            660                 665                 670
Leu Leu Pro Gln Pro Leu Glu
        675
```

<210> 3
<211> 1866
<212> DNA
<213> homo sapiens

<400> 3

```
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag      60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat     120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa     180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta     240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc     300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct     360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt     420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg     480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc     540
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga     600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt     660
```

```
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc     720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct     780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac     840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc     900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat     960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac    1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata    1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag    1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg    1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg    1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaacc    1320
ctgcagcagg tgaaaattat otcaataaac aacccgcttg ttttcctgaa tgcaaaaaaa    1380
ttttatactg atttaatgaa catgatccaa aaggaaaatg cctgtaatca gccacttgat    1440
gatatcagca agtgtgaaca aaacacattg cttaattccc tatccaatgg caactgcaat    1500
gaagaagctt cacagtcctg ccctaatgag aagtgttatt taatcctgga ttgcagtgga    1560
tttacctttt ttgactattc tggagtctcc atgcttgttg aggtttacat ggactgtaaa    1620
ggcaggagtg tggatgtatt gttagcccat tgtacagctt ccttgataaa agcaatgacg    1680
tattatggaa acctagactc agagaaacca attttttttg aatcggtatc tgctgcaata    1740
agtcatatcc attcaaataa gatggagtct cgctctgtct cccacgctgg agtgtcgcga    1800
tctcggctca ctgcaagctc cgcctcccgg gttcacgcct ttctcctgcc tcagcctctc    1860
gagtag                                                               1866
```

<210> 4
<211> 621
<212> PRT
<213> homo sapiens

<400> 4

```
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
 1               5                  10                  15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
            20                  25                  30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
        35                  40                  45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
    50                  55                  60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65                  70                  75                  80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
                85                  90                  95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
            100                 105                 110
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
```

```
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
            420                 425                 430
Val Asp Lys Ile Asp Trp Gly Thr Leu Gln Gln Val Lys Ile Ile Ser
        435                 440                 445
Ile Asn Asn Pro Leu Val Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp
    450                 455                 460
Leu Met Asn Met Ile Gln Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp
465                 470                 475                 480
Asp Ile Ser Lys Cys Glu Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn
                485                 490                 495
Gly Asn Cys Asn Glu Glu Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys
            500                 505                 510
Tyr Leu Ile Leu Asp Cys Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly
        515                 520                 525
Val Ser Met Leu Val Glu Val Tyr Met Asp Cys Lys Gly Arg Ser Val
    530                 535                 540
Asp Val Leu Leu Ala His Cys Thr Ala Ser Leu Ile Lys Ala Met Thr
545                 550                 555                 560
Tyr Tyr Gly Asn Leu Asp Ser Glu Lys Pro Ile Phe Phe Glu Ser Val
                565                 570                 575
Ser Ala Ala Ile Ser His Ile His Ser Asn Lys Met Glu Ser Arg Ser
            580                 585                 590
Val Ser His Ala Gly Val Ser Arg Ser Arg Leu Thr Ala Ser Ser Ala
        595                 600                 605
Ser Arg Val His Ala Phe Leu Leu Pro Gln Pro Leu Glu
    610                 615                 620
```

<210> 5
<211> 1992
<212> DNA
<213> homo sapiens

<400> 5
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag 60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat 120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa 180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta 240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc 300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct 360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt 420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg 480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc 540
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga 600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt 660
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc 720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct 780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac 840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc 900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat 960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac 1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata 1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag 1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg 1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg 1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaata 1320
tgggtcagta catatgtatt tacaatatgc tttgctgcca atgtgggact gctgtttggt 1380
gttgtttgta ccatagctat agtgatagga cgcttcccaa gagcaatgac tgtaagtata 1440
aaaaatatga aagwaatgga atttaaagtg aagacagaaa tggacagtga aaccctgcag 1500
caggtgaaaa ttatctcaat aaacaacccg cttgttttcc tgaatgcaaa aaaattttat 1560
actgatttaa tgaacatgat ccaaaaggaa aatgcctgta atcagccact tgatgatatc 1620
agcaagtgtg aacaaaacac attgcttaat tccctatcca atggcaactg caatgaagaa 1680
gcttcacagt cctgccctaa tgagaagtgt tatttaatcc tggattgcag tggatttacc 1740
ttttttgact attctggagt ctccatgctt gttgaggttt acatggactg taaaggcagg 1800
agtgtggatg tattgttagc ccattgtaca gcttccttga taaaagcaat gacgtattat 1860
ggaaacctag actcagagaa accaattttt tttgaatcgg tatctgctgc aataagtcat 1920
atccattcaa ataaggccag ttataaactg ttgtttgata acttggatct tccaacaatg 1980
ccaccgctct ga 1992

<210> 6
<211> 663
<212> PRT
<213> homo sapiens

<400> 6
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
1 5 10 15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
20 25 30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
35 40 45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
50 55 60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65 70 75 80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
85 90 95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
100 105 110

```
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
            420                 425                 430
Val Asp Lys Ile Asp Trp Gly Ile Trp Val Ser Thr Tyr Val Phe Thr
        435                 440                 445
Ile Cys Phe Ala Ala Asn Val Gly Leu Leu Phe Gly Val Val Cys Thr
    450                 455                 460
Ile Ala Ile Val Ile Gly Arg Phe Pro Arg Ala Met Thr Val Ser Ile
465                 470                 475                 480
Lys Asn Met Lys Glu Met Glu Phe Lys Val Lys Thr Glu Met Asp Ser
                485                 490                 495
Glu Thr Leu Gln Gln Val Lys Ile Ile Ser Ile Asn Asn Pro Leu Val
            500                 505                 510
Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp Leu Met Asn Met Ile Gln
        515                 520                 525
Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp Asp Ile Ser Lys Cys Glu
    530                 535                 540
Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn Gly Asn Cys Asn Glu Glu
545                 550                 555                 560
```

```
Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys Tyr Leu Ile Leu Asp Cys
                565                 570                 575
Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly Val Ser Met Leu Val Glu
            580                 585                 590
Val Tyr Met Asp Cys Lys Gly Arg Ser Val Asp Val Leu Leu Ala His
        595                 600                 605
Cys Thr Ala Ser Leu Ile Lys Ala Met Thr Tyr Tyr Gly Asn Leu Asp
    610                 615                 620
Ser Glu Lys Pro Ile Phe Phe Glu Ser Val Ser Ala Ala Ile Ser His
625                 630                 635                 640
Ile His Ser Asn Lys Ala Ser Tyr Lys Leu Leu Phe Asp Asn Leu Asp
                645                 650                 655
Leu Pro Thr Met Pro Pro Leu
            660
```

<210> 7
<211> 1818
<212> DNA
<213> homo sapiens

<400> 7

```
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag      60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat     120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa     180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta     240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc     300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct     360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt     420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg     480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc     540
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga     600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt     660
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc     720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct     780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac     840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc     900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat     960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac    1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata    1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag    1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg    1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg    1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaacc    1320
ctgcagcagg tgaaaattat ctcaataaac aacccgcttg ttttcctgaa tgcaaaaaaa    1380
ttttatactg atttaatgaa catgatccaa aaggaaaatg cctgtaatca gccacttgat    1440
gatatcagca agtgtgaaca aaacacattg cttaattccc tatccaatgg caactgcaat    1500
gaagaagctt cacagtcctg ccctaatgag aagtgttatt taatcctgga ttgcagtgga    1560
tttacctttt ttgactattc tggagtctcc atgcttgttg aggtttacat ggactgtaaa    1620
ggcaggagtg tggatgtatt gttagcccat tgtacagctt ccttgataaa agcaatgacg    1680
tattatggaa acctagactc agagaaacca attttttttg aatcggtatc tgctgcaata    1740
agtcatatcc attcaaataa ggccagttat aaactgttgt ttgataactt ggatcttcca    1800
acaatgccac cgctctga                                                  1818
```

<210> 8
<211> 605
<212> PRT

<213> homo sapiens

<400> 8

```
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
 1               5                  10                  15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
            20                  25                  30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
        35                  40                  45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
    50                  55                  60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65                  70                  75                  80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
                85                  90                  95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
            100                 105                 110
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
```

```
        420                 425                 430
Val Asp Lys Ile Asp Trp Gly Thr Leu Gln Gln Val Lys Ile Ile Ser
        435                 440                 445
Ile Asn Asn Pro Leu Val Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp
    450                 455                 460
Leu Met Asn Met Ile Gln Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp
465                 470                 475                 480
Asp Ile Ser Lys Cys Glu Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn
                485                 490                 495
Gly Asn Cys Asn Glu Glu Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys
            500                 505                 510
Tyr Leu Ile Leu Asp Cys Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly
        515                 520                 525
Val Ser Met Leu Val Glu Val Tyr Met Asp Cys Lys Gly Arg Ser Val
    530                 535                 540
Asp Val Leu Leu Ala His Cys Thr Ala Ser Leu Ile Lys Ala Met Thr
545                 550                 555                 560
Tyr Tyr Gly Asn Leu Asp Ser Glu Lys Pro Ile Phe Phe Glu Ser Val
                565                 570                 575
Ser Ala Ala Ile Ser His Ile His Ser Asn Lys Ala Ser Tyr Lys Leu
            580                 585                 590
Leu Phe Asp Asn Leu Asp Leu Pro Thr Met Pro Pro Leu
        595                 600                 605
```

<210> 9
<211> 1971
<212> DNA
<213> homo sapiens

<400> 9

```
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag      60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat     120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa     180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta     240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc     300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct     360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt     420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg     480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc     540
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga     600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt     660
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc     720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct     780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac     840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc     900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat     960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac    1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata    1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag    1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg    1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg    1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaata    1320
tgggtcagta catatgtatt tacaatatgc tttgctgcca atgtgggact gctgtttggt    1380
gttgtttgta ccatagctat agtgatagga cgcttcccaa gagcaatgac tgtaagtata    1440
aaaaatatga aagwaatgga atttaaagtg aagacagaaa tggacagtga aaccctgcag    1500
caggtgaaaa ttatctcaat aaacaacccg cttgttttcc tgaatgcaaa aaaattttat    1560
```

```
actgatttaa tgaacatgat ccaaaaggaa aatgcctgta atcagccact tgatgatatc    1620
agcaagtgtg aacaaaacac attgcttaat tccctatcca atggcaactg caatgaagaa    1680
gcttcacagt cctgccctaa tgagaagtgt tatttaatcc tggattgcag tggatttacc    1740
ttttttgact attctggagt ctccatgctt gttgaggttt acatggactg taaaggcagg    1800
agtgtggatg tattgttagc ccattgtaca gcttccttga taaaagcaat gacgtattat    1860
ggaaacctag actcagagaa accaattttt tttgaatcgg tatctgctgc aataagtcat    1920
atccattcaa ataagaattt gagcaaactc agtgaccaca gtgaagtctg a              1971
```

<210> 10
<211> 656
<212> PRT
<213> homo sapiens

<400> 10

```
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
 1               5                  10                  15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
            20                  25                  30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
        35                  40                  45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
    50                  55                  60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65                  70                  75                  80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
                85                  90                  95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
            100                 105                 110
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
```

```
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
            420                 425                 430
Val Asp Lys Ile Asp Trp Gly Ile Trp Val Ser Thr Tyr Val Phe Thr
        435                 440                 445
Ile Cys Phe Ala Ala Asn Val Gly Leu Leu Phe Gly Val Val Cys Thr
    450                 455                 460
Ile Ala Ile Val Ile Gly Arg Phe Pro Arg Ala Met Thr Val Ser Ile
465                 470                 475                 480
Lys Asn Met Lys Glu Met Glu Phe Lys Val Lys Thr Glu Met Asp Ser
                485                 490                 495
Glu Thr Leu Gln Gln Val Lys Ile Ile Ser Ile Asn Asn Pro Leu Val
            500                 505                 510
Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp Leu Met Asn Met Ile Gln
        515                 520                 525
Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp Asp Ile Ser Lys Cys Glu
    530                 535                 540
Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn Gly Asn Cys Asn Glu Glu
545                 550                 555                 560
Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys Tyr Leu Ile Leu Asp Cys
                565                 570                 575
Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly Val Ser Met Leu Val Glu
            580                 585                 590
Val Tyr Met Asp Cys Lys Gly Arg Ser Val Asp Val Leu Leu Ala His
        595                 600                 605
Cys Thr Ala Ser Leu Ile Lys Ala Met Thr Tyr Tyr Gly Asn Leu Asp
    610                 615                 620
Ser Glu Lys Pro Ile Phe Phe Glu Ser Val Ser Ala Ala Ile Ser His
625                 630                 635                 640
Ile His Ser Asn Lys Asn Leu Ser Lys Leu Ser Asp His Ser Glu Val
                645                 650                 655
```

<210> 11
<211> 1797
<212> DNA
<213> homo sapiens

<400> 11

```
atgacaggag caaagaggaa aaagaaaagc atgctttgga gcaagatgca tacccccag      60
tgtgaagaca ttatacagtg gtgtagaagg cgactgccca ttttggattg ggcaccacat     120
tacaatctga aagaaaactt gcttccagac actgtgtctg ggataatgtt ggcagttcaa     180
caggtgaccc aaggattggc ctttgctgtt ctctcatctg tgcacccagt gtttggttta     240
tatgggtctc tgtttcctgc cataatttat gccatatttg gaatgggaca tcatgttgcc     300
acaggcacct ttgccttgac atccttaata tcagccaacg ccgtggaacg gattgtccct     360
cagaacatgc agaatctcac cacacagagt aacacaagcg tgctgggctt atccgacttt     420
gaaatgcaaa ggatccacgt tgctgcagca gtttccttct tgggaggtgt gattcaggtg     480
gccatgtttg tgctgcaact gggcagtgcc acatttgtgg tcacagagcc tgtgatcagc     540
```

```
gcaatgacaa ctggggctgc cacccatgtg gtgacttcac aagtcaaata tctcttggga     600
atgaaaatgc catatatatc cggaccactt ggattctttt atatttatgc atatgttttt     660
gaaaacatca agtctgtgcg actggaagca ttgcttttat ccttgctgag cattgtggtc     720
cttgttcttg ttaaagagct gaatgaacag tttaaaagga aaattaaagt tgttcttcct     780
gtagatttag ttttgattat tgctgcatca tttgcttgtt attgcaccaa tatggaaaac     840
acatatggat tagaagtagt tggtcatatt ccacaaggaa ttccctcacc tagagctccc     900
ccgatgaaca tcctctctgc ggtgatcact gaagctttcg gagtggcact tgtaggctat     960
gtggcctcac tggctcttgc tcaaggatct gccaaaaaat tcaaatattc aattgatgac    1020
aaccaggaat ttttggccca tggcctcagc aatatagttt cttcattttt cttctgcata    1080
ccaagtgctg ctgccatggg aaggacggct ggcctgtaca gcacaggagc gaagacacag    1140
gtggcttgtc taatatcttg cattttcgtc cttatagtca tctatgcaat aggacctttg    1200
ctttactggc tgcccatgtg tgtccttgca agcattattg ttgtgggact gaagggaatg    1260
ctaatacagt tccgagattt aaaaaaatat tggaatgtgg ataaaatcga ttggggaacc    1320
ctgcagcagg tgaaaattat ctcaataaac aacccgcttg ttttcctgaa tgcaaaaaaa    1380
ttttatactg atttaatgaa catgatccaa aaggaaaatg cctgtaatca gccacttgat    1440
gatatcagca agtgtgaaca aaacacattg cttaattccc tatccaatgg caactgcaat    1500
gaagaagctt cacagtcctg ccctaatgag aagtgttatt taatcctgga ttgcagtgga    1560
tttacctttt ttgactattc tggagtctcc atgcttgttg aggtttacat ggactgtaaa    1620
ggcaggagtg tggatgtatt gttagcccat tgtacagctt ccttgataaa agcaatgacg    1680
tattatggaa acctagactc agagaaacca attttttttg aatcggtatc tgctgcaata    1740
agtcatatcc attcaaataa gaatttgagc aaactcagtg accacagtga agtctga       1797
```

<210> 12
<211> 598
<212> PRT
<213> homo sapiens

<400> 12

```
Met Thr Gly Ala Lys Arg Lys Lys Lys Ser Met Leu Trp Ser Lys Met
 1               5                  10                  15
His Thr Pro Gln Cys Glu Asp Ile Ile Gln Trp Cys Arg Arg Arg Leu
            20                  25                  30
Pro Ile Leu Asp Trp Ala Pro His Tyr Asn Leu Lys Glu Asn Leu Leu
        35                  40                  45
Pro Asp Thr Val Ser Gly Ile Met Leu Ala Val Gln Gln Val Thr Gln
    50                  55                  60
Gly Leu Ala Phe Ala Val Leu Ser Ser Val His Pro Val Phe Gly Leu
65                  70                  75                  80
Tyr Gly Ser Leu Phe Pro Ala Ile Ile Tyr Ala Ile Phe Gly Met Gly
                85                  90                  95
His His Val Ala Thr Gly Thr Phe Ala Leu Thr Ser Leu Ile Ser Ala
            100                 105                 110
Asn Ala Val Glu Arg Ile Val Pro Gln Asn Met Gln Asn Leu Thr Thr
        115                 120                 125
Gln Ser Asn Thr Ser Val Leu Gly Leu Ser Asp Phe Glu Met Gln Arg
    130                 135                 140
Ile His Val Ala Ala Ala Val Ser Phe Leu Gly Gly Val Ile Gln Val
145                 150                 155                 160
Ala Met Phe Val Leu Gln Leu Gly Ser Ala Thr Phe Val Val Thr Glu
                165                 170                 175
Pro Val Ile Ser Ala Met Thr Thr Gly Ala Ala Thr His Val Val Thr
            180                 185                 190
Ser Gln Val Lys Tyr Leu Leu Gly Met Lys Met Pro Tyr Ile Ser Gly
        195                 200                 205
Pro Leu Gly Phe Phe Tyr Ile Tyr Ala Tyr Val Phe Glu Asn Ile Lys
    210                 215                 220
```

```
Ser Val Arg Leu Glu Ala Leu Leu Leu Ser Leu Leu Ser Ile Val Val
225                 230                 235                 240
Leu Val Leu Val Lys Glu Leu Asn Glu Gln Phe Lys Arg Lys Ile Lys
                245                 250                 255
Val Val Leu Pro Val Asp Leu Val Leu Ile Ile Ala Ala Ser Phe Ala
            260                 265                 270
Cys Tyr Cys Thr Asn Met Glu Asn Thr Tyr Gly Leu Glu Val Val Gly
        275                 280                 285
His Ile Pro Gln Gly Ile Pro Ser Pro Arg Ala Pro Pro Met Asn Ile
    290                 295                 300
Leu Ser Ala Val Ile Thr Glu Ala Phe Gly Val Ala Leu Val Gly Tyr
305                 310                 315                 320
Val Ala Ser Leu Ala Leu Ala Gln Gly Ser Ala Lys Lys Phe Lys Tyr
                325                 330                 335
Ser Ile Asp Asp Asn Gln Glu Phe Leu Ala His Gly Leu Ser Asn Ile
            340                 345                 350
Val Ser Ser Phe Phe Phe Cys Ile Pro Ser Ala Ala Ala Met Gly Arg
        355                 360                 365
Thr Ala Gly Leu Tyr Ser Thr Gly Ala Lys Thr Gln Val Ala Cys Leu
    370                 375                 380
Ile Ser Cys Ile Phe Val Leu Ile Val Ile Tyr Ala Ile Gly Pro Leu
385                 390                 395                 400
Leu Tyr Trp Leu Pro Met Cys Val Leu Ala Ser Ile Ile Val Val Gly
                405                 410                 415
Leu Lys Gly Met Leu Ile Gln Phe Arg Asp Leu Lys Lys Tyr Trp Asn
            420                 425                 430
Val Asp Lys Ile Asp Trp Gly Thr Leu Gln Gln Val Lys Ile Ile Ser
        435                 440                 445
Ile Asn Asn Pro Leu Val Phe Leu Asn Ala Lys Lys Phe Tyr Thr Asp
    450                 455                 460
Leu Met Asn Met Ile Gln Lys Glu Asn Ala Cys Asn Gln Pro Leu Asp
465                 470                 475                 480
Asp Ile Ser Lys Cys Glu Gln Asn Thr Leu Leu Asn Ser Leu Ser Asn
                485                 490                 495
Gly Asn Cys Asn Glu Glu Ala Ser Gln Ser Cys Pro Asn Glu Lys Cys
            500                 505                 510
Tyr Leu Ile Leu Asp Cys Ser Gly Phe Thr Phe Phe Asp Tyr Ser Gly
        515                 520                 525
Val Ser Met Leu Val Glu Val Tyr Met Asp Cys Lys Gly Arg Ser Val
    530                 535                 540
Asp Val Leu Leu Ala His Cys Thr Ala Ser Leu Ile Lys Ala Met Thr
545                 550                 555                 560
Tyr Tyr Gly Asn Leu Asp Ser Glu Lys Pro Ile Phe Phe Glu Ser Val
                565                 570                 575
Ser Ala Ala Ile Ser His Ile His Ser Asn Lys Asn Leu Ser Lys Leu
            580                 585                 590
Ser Asp His Ser Glu Val
        595
```

<210> 13
<211> 2420
<212> DNA
<213> homo sapiens

<400> 13
ctccttcaga taagaattca agctttgaca ttgtaaacca cagacgaatt ggagcttggc 60

attgaaagga ggtgttctgc aatgattttt tttcttgttt agagaagttt acttctacaa 120
gaagaaatct gaaaaatgac aggagcaaag aggaaaaaga aaagcatgct ttggagcaag 180
atgcataccc cccagtgtga agacattata cagtggtgta gaaggcgact gcccattttg 240
gattgggcac cacattacaa tctgaaagaa aacttgcttc cagacactgt gtctgggata 300
atgttggcag ttcaacaggt gacccaagga ttggcctttg ctgttctctc atctgtgcac 360
ccagtgtttg gtttatatgg gtctctgttt cctgccataa tttatgccat atttggaatg 420
ggacatcatg ttgccacagg caccttttgcc ttgacatcct taatatcagc caacgccgtg 480
gaacggattg tccctcagaa catgcagaat ctcaccacac agagtaacac aagcgtgctg 540
ggcttatccg actttgaaat gcaaaggatc cacgttgctg cagcagtttc cttcttggga 600
ggtgtgattc aggtggccat gtttgtgctg caactgggca gtgccacatt tgtggtcaca 660
gagcctgtga tcagcgcaat gacaactggg gctgccaccc atgtggtgac ttcacaagtc 720
aaatatctct tgggaatgaa aatgccatat atatccggac cacttggatt cttttatatt 780
tatgcatatg tttttgaaaa catcaagtct gtgcgactgg aagcattgct tttatccttg 840
ctgagcattg tggtccttgt tcttgttaaa gagctgaatg aacagtttaa aaggaaaatt 900
aaagttgttc ttcctgtaga tttagttttg attattgctg catcatttgc ttgttattgc 960
accaatatgg aaaacacata tggattagaa gtagttggtc atattccaca aggaattccc 1020
tcacctagag ctcccccgat gaacatcctc tctgcggtga tcactgaagc tttcggagtg 1080
gcacttgtag gctatgtggc ctcactggct cttgctcaag gatctgccaa aaaattcaaa 1140
tattcaattg atgacaacca ggaatttttg gcccatggcc tcagcaatat agtttcttca 1200
tttttcttct gcataccaag tgctgctgcc atgggaagga cggctggcct gtacagcaca 1260
ggagcgaaga cacaggtggc ttgtctaata tcttgcattt tcgtccttat agtcatctat 1320
gcaataggac ctttgcttta ctggctgccc atgtgtgtcc ttgcaagcat tattgttgtg 1380
ggactgaagg gaatgctaat acagttccga gatttaaaaa aatattggaa tgtggataaa 1440
atcgattggg gaatatgggt cagtacatat gtatttacaa tatgctttgc tgccaatgtg 1500
ggactgctgt ttggtgttgt ttgtaccata gctatagtga taggacgctt cccaagagca 1560
atgactgtaa gtataaaaaa tatgaaagwa atggaattta aagtgaagac agaaatggac 1620
agtgaaaccc tgcagcaggt gaaaattatc tcaataaaca acccgcttgt tttcctgaat 1680
gcaaaaaaat tttatactga tttaatgaac atgatccaaa aggaaaatgc ctgtaatcag 1740
ccacttgatg atatcagcaa gtgtgaacaa aacacattgc ttaattccct atccaatggc 1800
aactgcaatg aagaagcttc acagtcctgc cctaatgaga agtgttattt aatcctggat 1860
tgcagtggat ttacctttttt tgactattct ggagtctcca tgcttgttga ggtttacatg 1920
gactgtaaag gcaggagtgt ggatgtattg ttagcccatt gtacagcttc cttgataaaa 1980
gcaatgacgt attatggaaa cctagactca gagaaaccaa tttttttttga atcggtatct 2040
gctgcaataa gtcatatcca ttcaaataag aatttgagca aactcagtga ccacagtgaa 2100
gtctgagacc cttttgtcac agtacagctc ttgtctttac caactgcctg aagaggccat 2160
atgctggcat tttgcacaac tttttggttg tttagatcct acagatgacc tctgctacaa 2220
taagtacgat gtgacttagt aactgcatag cagttggaaa gaactgccaa ctttttttttc 2280
tcatttttgt tagtaagaag attcgcttag ttattttatg taaaaatcag tatgtgttta 2340
gttttagtgt actgaagggt aaacatggtt ttatttttatt ttaccatatt attttgggtt 2400
ggtttatttc tattgggctg 2420

HPS Trailer Page
for

# Walk-Up_Printing

**UserID:** BASI

**Printer:** rem_04c70_gbuqptr

## Summary

| Document | Pages | Printed | Missed | Copies |
|---|---|---|---|---|
| WO000194583 | 48 | 48 | 0 | 1 |
| Total (1) | 48 | 48 | 0 | - |